- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Opinion
Video
Overcoming Treatment Barriers in Vitiligo: From Insurance Coverage to Patient Adherence
Author(s):
Andrew Alexis, MD, MPH, reviews the case of a 66-year-old woman who presented with depigmented patches and provides clinical insights on barriers typically encountered during the management of this condition.
Video Player is loading.
Video content above is prompted by the following questions:
- Where would you go from here, treatment-wise?
- What is your experience combining topical therapy with NB-UVB phototherapy?
- What are the unique challenges and benefits of using narrowband UVB phototherapy for vitiligo in patients with darker skin color?
- How do you manage the logistical challenges patients might face with frequent phototherapy sessions?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Determining Follow-Up Approach in Melanoma Based on GEP Risk Level
Key Takeaways on GEP Testing in Melanoma and SCC
De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC
Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma
Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma
Utility of Molecular Testing in Skin Cancer Risk Assessment
Limitations and Challenges in Skin Cancer Staging Systems
Laboratory Monitoring for JAK Inhibitors and Key Takeaways
Options for Eyebrow and Eyelash Regrowth in a 32-Year-Old Female With Alopecia Areata
Discussing Efficacy and Safety of JAK Inhibitors With Patients and Caregivers
Related Content
